Multiple methods currently exist for identification of RBC antibodies, including manual tube methods with various enhancement reagents as well as advanced automated platforms using either gel microcolumns or solid-phase RBC adherence assays (SPRCA). Studies have shown increased sensitivity to detect RBC antibodies with gel and solid-phase assays when compared to manual tube methods. [1] [2] [3] One comparison of seven methods of antibody detection found that the SPRCA showed the highest sensitivity, followed closely by gel microcolumn techniques. 2 The advantages of augmented sensitivity in these methods is offset by their increased detection of antibodies, which are seldom implicated in hemolytic transfusion reactions (so-called antibodies of minor clinical significance). In addition, the augmented sensitivity results in nonspecific reactivity patterns that are often characterized as "inconclusive" or "antibodies of undetermined specificity." 4 Ideally, a method that detects all clinically significant antibodies without detecting those of minor clinical importance is preferred. The analysis and investigation of inconclusive or minor significant antibodies utilizes scarce personnel resources and may delay provision of compatible blood components. 5 Many institutions use a combination of methods for antibody identification (ABID).
Over a 3-month time period, our transfusion service laboratory observed a significant increase in the number of positive RBC antibody screens (AS) with inconclusive antibodies identified using SPRCA for ABID. Concomitantly, the transfusion service upper management also recognized that the amount of time and effort expended to investigate inconclusive antibodies resulted in little (or unknown) benefit to the patient. Interestingly, AS and ABID were most often performed using automated SPRCA and manual tube methods alternately or in duplicate, which increased turnaround time or delayed RBC crossmatches. It also became problematic, as we serve one of the busiest solid organ transplant and trauma centers in the United States. Furthermore, the transfusion service staff were not guided as to which technique (SPRCA vs manual tube method) should be used as gold standard to result AS and ABID in the presence of an inconclusive antibody, as the ABID result would often differ from one method to another. During an internal audit by our blood bank quality assurance specialist, this discrepancy and lack of guidance was identified as a deficiency, requiring corrective action. Thus, a quality improvement (QI) process had to be implemented. In order to develop this specific QI plan, we embarked on a retrospective analysis of the RBC ABID files over a 3-month time period. Upon completion of the analysis, we revised the reference workflow for RBC AS and ABID by keeping the automated SPRCA method as the principal AS platform and by recognizing the manual tube method as the primary method for ABID. Data on the number of AS and ABID are presented pre-and postimplementation of the revised reference workflow.
Methods

RBC SA-SPRCA Automated Method
In our large, urban, hospital-based transfusion service, initial RBC AS is performed using the SPRCA method using the Capture-R Ready Screen (Immucor, Norcross, GA) on the ECHO automated immunohematology platform (Immucor). Patient plasma is mixed with low ionic strength solution (LISS) (Capture-LISS, Immucor) additive in a ratio of 2:1 and added to a RBC monolayer covered polystyrene microplate-well (Capture-R Ready Screen) to identify RBC antibodies bound to the membrane antigens. After a 10-minute incubation with patient plasma, the plates are washed to remove unbound antibody, and anti-IgG indicator RBCs are added to the microwell (Capture-R Ready Indicator Red Cells, Immucor). A positive reaction is indicated by RBC adherence to the microwell surface, whereas the formation of a RBC button in the center of the microwell denotes a negative test result.
RBC AS-Manual Serologic Tube Method
Using the manual screening method, the patient's plasma is incubated at 37°C with reagent RBC of known phenotype (Panoscreen I, II, and III Reagent Red Blood Cells, Immucor) and either LISS or polyethylene glycol (PEG) solutions (Immucor). LISS increases the rate of antigen-antibody reaction and shortens the required incubation time to 10 minutes to detect most antibodies. In contrast, with PEG reagent, the incubation time can be extended to 30 minutes to enhance the reactivity of weak antibodies. Following the 37°C incubation, the sample is washed with saline before the addition of anti-human globulin (AHG) Coombs reagent (Immucor) and inspected for agglutination and hemolysis, which indicates the presence of RBC antibodies in the patient plasma. In the manual tube method for AS/ABID, an autocontrol is performed on all samples. In the autocontrol, patient RBCs are incubated with patient plasma, followed by the addition of AHG reagent. If the autocontrol is positive, then a reflex direct Coombs/AHG test (DAT) with polyspecific and monoclonal reagents (AHG, anti-IgG, anti-C3d, polyclonal and monocolonal, Immucor) would be performed. If the autocontrol is negative following the addition of AHG, a DAT is not indicated per standard operating procedure (SOP).
Original ABID Workflow Procedure
In the original RBC reference workflow SOP, AS and ABID were initially performed by SPRCA. ABID by SPRCA was performed using Capture-R Ready ID Extend I (D-Positive Panel) or Capture-R Ready-ID Extend II (D-Negative Panel) (Immucor), depending on AS results using the Capture-R Ready-Screen. If ABID was inconclusive, AS and ABID were repeated using manual serologic LISS and/or PEG tube methods (Immucor). But on review of the SOP by the quality assurance specialist, it was noted that if ABID results were different with the tube method compared to SPRCA method, the SOP gave no guidance on how to finalize the results. Specifically, if the manual serologic tube method showed negative reactivity despite inconclusive reactivity using the SPRCA method, the AS and ABID were resulted as positive and inconclusive respectively. PEG Coombs-crossmatchedcompatible RBCs were then issued for transfusion.
Evaluation of the RBC AS and ABID Workflow and Procedure
A retrospective analysis of ABID patient samples with positive AS using the original AS and ABID procedure was performed during a 3-month time period from December 2013 to February 2014. The number of ABID with RBC antibody identified was determined and compared to those with inconclusive reactivity patterns. Based on the analysis of inconclusive ABID, the reference workflow was revised as a QI process. The number of inconclusive ABID results were then reviewed over another 3-month time period, postimplementation, from July 2014 to September 2014.
Survey of AS and ABID Methods Used at Different Institutions
In order to develop a strategy to standardize the AS and ABID process, we contacted the transfusion service medical directors (n = 3) practicing at other institutions of similar size and clinical activity. We asked the following questions: (1) What method does your transfusion service reference laboratory primarily use for AS and ABID? (2) What is your gold standard method for ABID?
Cost-Saving Analysis and Turnaround Improvement
The cost analysis of potential savings following implementation of the QI process was estimated by the decrease in the number of inconclusive antibody results and the elimination of both SPRCA panels and Coombs RBC crossmatches. The turnaround time improvement was calculated based on the time saved and originally required for additional SPRCA (35 minutes) and Coombs crossmatches (45 minutes) previously performed on all samples resulting with inconclusive antibody and no previous specific antibody identified.
Results
Analysis of RBC AS and ABID Results Preimplementation
From December 2013 to February 2014, there were 743 positive AS by SPRCA out of 12,886 patient samples (6%). AS positive reactivity by SPRCA increased from 5% to 8% over the 3 month time period ❚Table 1❚.
Concomitantly, the percentage of ABID with inconclusive antibody results increased from 8% (18/221) to 12% (39/317) of total positive AS, with an average of 26 per month. The percent increase in inconclusive antibody results was associated with a corresponding increase in reference workups using the manual method to resolve inconclusive ABID results by SPRCA (data not shown).
AS and ABID Methods Used at Different Institutions
Three institutions of similar size and clinical activities were surveyed in reference to the methods used for RBC AS and ABID. At one institution, the RBC reference laboratory used SPRCA method for AS only, and the manual tube (PEG) method for ABID, which was the gold standard method. At another institution SPRCA was used for AS as well, and the gel and the manual tube (PEG) methods were used for both AS and ABID, but the PEG tube method was considered the gold standard method. At the third institution, the gel method was used for both AS and ABID and was considered the gold standard method.
Intervention
Based on the need to standardize the AS and ABID process to improve patient safety and efficiency, the results of the AS/ABID analysis as well as the institutional survey were presented to the transfusion service executive management for decision on the optimal process change. The following process change was proposed and agreed upon. SPRCA would be used for initial AS, positive AS results by SPRCA would now reflex to manual LISS and/or PEG tube methods for confirmation and ABID. Unlike the previous workflow, if AS reflex testing is negative by manual tube testing, the patient AS is resulted as negative. Electronic crossmatched RBC may then be issued more efficiently, if ordered. Upon secondary review of the SPRCA-positive/manualtube-negative AS result by a reference technical specialist, the ABID may be performed by SPRCA for further characterization of the SPRCA-positive/manual-tube-negative AS reactivity ❚Figure 1B❚. All positive AS and ABIDs were reviewed by a reference technical specialist on the next business day. The specialist may request a SPRCA ABID if there is a difference in reaction strength (>2+) in conjunction with a probable pattern on the AS panel. This process was applied to the analysis of all patient samples, regardless of severity, antibody history, on-going surgery, or need for emergency transfusions. Any new specific antibody identified by the SPRCA method upon secondary review generates an amendment to the original report. The potential for acute hemolysis from unidentified antibodies was considered low since it was not demonstrable using the gold standard manual tube testing method. AS and ABID results were then reviewed for 3 months following implementation of the revised reference workflow procedure.
Assessment of Revised RBC AS and ABID Workflow and Procedure
RBC ABID reference workflow was adjusted by using manual LISS/PEG tube method as the gold standard ABID method with selective use of SPRCA, as judged appropriate upon secondary review by a reference technical specialist. Over the 3-month period post implementation of the revised workflow, there were 827 (6%) positive AS by SPRCA out of 13,914 patient samples. Of those AS tests, positive by SPRCA, 235 (28%) were subsequently negative by manual methods. The rate of inconclusive antibody results decreased from 26 per month (79/743, 11%) preimplementation to 6 per month (19/827, 2%) postimplementation of the revised reference workflow ( Table 1) . The SPRCA method used for ABID as appropriately indicated on reference technical specialist review ( Figure 1B ) allowed the detection of 30 clinically significant RBC antibodies (in 29 patients) otherwise not demonstrable by the manual ABID tube method, most commonly anti-E and anti-D. The clinically significant antibodies subsequently identified included: anti-E (27%), anti-D (27%), anti-Jk a (17%), anti-C (13%), anti-Jk b (10%), anti-K (3%) and anti-S (3%). Two of the 29 patients presenting with a new RBC antibody on secondary review had just been transfused with RBC units unscreened for those respective antigens. The RBC units were not tested for the subsequently identified antigens. Both patients had a subsequent routine ABO type and screen sample drawn 2 to 4 days after transfusion. These samples showed no visible hemolysis and the autocontrol was negative (indicating that a DAT was not required per SOP). Pretransfusion hemoglobin and hematocrit were 6.6 to 6.7 g/dL and 20.2% to 20.3%, respectively. The hemoglobin following transfusion of the antigen untested units showed appropriate rise in hemoglobin of 1.4 to 1.5 g/dL and in hematocrit of 3% to 4%. Since hemolysis may develop more than 4 days after transfusion, the hemoglobin and hematocrit were observed for the 5 days following transfusion of the untested RBC units. Both hemoglobin and hematocrit remained stable at 7.8 to 8.9 g/dL and 22.9% to 27.2% on subsequent routine samples for the 5 days following transfusions.
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❚Figure 1❚ Algorithm for inconclusive RBC antibody identification (ABID) using the reflex manual tube method (A) and the solid-phase RBC adherence assay (SPRCA) on secondary review (B), to improve crossmatch (CXM) turnaround time.
Cost and Turnaround Analysis
In the 3 months following implementation of using SPRCA ABID only on secondary-reference review ( Figure 1B) , we eliminated 205 SPRCA panels and associated full Coombs crossmatches. The new process allowed cost savings in supplies and full-time equivalent (FTE) time. For each SPRCA test and associated Coombs crossmatch not performed, the cost decreased by $75, which includes a cost of $35 for supplies and a cost of $40 for the 80 minute time of an FTE. The estimated total savings over the 3-month period was $15,375, with an estimated annual savings of $61,500. The turnaround time for issuing crossmatched RBC for patient samples presenting with inconclusive antibodies and no specific alloantibody was reduced by 45 minutes.
Discussion
Upon reevaluation of our current RBC antibody reference workflow, it was shown that the indication for use of either SPRCA and/or manual LISS/PEG tube method for ABID needed to be redefined. Furthermore, on surveying other institutions, it was found that the manual tube method often served as the reference gold standard method for ABID, eschewing more sensitive techniques. In light of these data, the workflow for RBC AS and ABID was revised. A revision of the SOP was then implemented including the following two changes: (1) to use manual tube testing as the primary method for ABID on patient samples with positive AS by SPRCA ❚Figure 1A❚; and (2) to allow ABID using SPRCA method only on secondary review of the ABID workup by a reference specialist capable of discerning when SPRCA ABID is appropriate ( Figure 1B) . As a result of the SOP revisions, the number of ABID resulting in inconclusive antibodies decreased significantly (Table 1) and facilitated electronic crossmatch orders as appropriate. Reducing unnecessary ABID testing by SPRCA also reduced costs in supplies and reagents. Even though the automation of SPRCA method had eliminated personnel costs associated with manual testing, this potential saving was offset by the additional cost associated with extensive or duplicate testing to resolve the inconclusive results.
A review by Yamada et al 3 on the techniques used for RBC ABID showed that SPRCA was a useful complementary ABID method to the tube method, but that fewer than 3% of transfusion service laboratories use SPRCA for routine ABID. More recent data by Liu and Grossman 4 showed that of 18 surveyed transfusion services, eight of these use SPRCA for antibody screening, while only four of those used SPRCA for ABID. The SPRCA method may be considered more sensitive but less specific than the manual method for ABID and determination of antibody specificity. 3 Our transfusion service leadership reviewed the clinical needs of the patient population at our institution and observed a high ratio (1:3) of patients with severe acuity. Subsequently, the decision to meet rapid turnaround times for RBC AS/ABID and crossmatches became more important than increased sensitivity with less specificity, as was the case using primarily SPRCA for ABID. Previous studies by Bunker et al 6 compared sensitivity and specificity of the SPRCA method vs the manual tube method. Similarly, they concluded that the greater sensitivity of the SPRCA method was outweighed by the increased number of inconclusive antibody results, for which resolution increased reference work up time and delays in issuing crossmatched RBC units. 6 Thus, we admitted that the SPRCA vs manual method algorithm was to be balanced and adapted to the clinical situation, by prioritizing turnaround time in the acute setting of bleeding vs sensitivity of the method in more stable patients.
Our primary concern in using the less sensitive manual method for ABID is the potential risk to patient safety if a newly forming antibody is missed. Many authors have questioned the hazards of transfusing components to critically ill patients with inconclusive antibodies. [7] [8] [9] However, data on the subject are sparse. In the early 1990s, Issitt and colleagues 10 retrospectively analyzed samples with negative AS via LISS tube manual methods from 10,000 recently transfused patients. All samples were subsequently tested with an enzyme treated AS method and phenotyping of the transfused RBC units was performed to determine which units were antigen positive. Nineteen patients received RBC units antigen positive for their corresponding antibody, 18 had no evidence of a transfusion reaction, while one patient with anti-c had a delayed hemolytic reaction. 10 Using the SPRCA method for ABID, as appropriately indicated on secondary reference review, allowed the detection of clinically significant antibodies primarily anti-E, anti-D, anti-C, and anti-Kidd (Jk a , Jk b ), which was consistent with previous reports. 2, 3 Interestingly, most studies using SPRCA showed anti-Jk b to be detectable only by solid phase methods.
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In conclusion, inconclusive RBC antibodies are more likely to be demonstrable by SPRCA method compared to manual tube method and may delay the issue of crossmatched compatible RBC units. Nevertheless, the RBC antibody reference workflow may be designed to use SPRCA and serologic manual tube methods for AS and ABID respectively in order to minimize delays in issuing compatible blood without jeopardizing safety.
